Company intelligence / Profile preview

Asylia Therapeutics

Houston, Texas, United Statesasyliatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Asylia’s lead program ASY‑77A has demonstrated complete regression in preclinical models of multiple cancers by enhancing antigen presentation and activating dendritic cells and T-cells. The company’s assets are being humanized for first-in-human safety and proof-of-concept studies. No clinical results in humans have been reported as of May 2025[4][5].

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Monoclonal antibodiesBispecific killer cell engagers (BiKE)
Industry: Biotech

Drug pipeline

3 assets

ASY-77A

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Sporos BioventuresJLabsCancer Prevention & Research Institute of Texas

Beyond the preview

Go deeper on Asylia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asylia Therapeutics.

Explore the full profile